Search projects
11 projects found
AB-Direct
Antibiotic distribution and recovery in tissue
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials
1
AMR Accelerator
Antimicrobial Resistance Accelerator. Umbrella programme comprising the IMI projects AB-DIRECT, COMBINE, ERA4TB, GNA NOW, PRIMAVERA, RespiriNTM, RespiriTB, TRIC-TB and UNITE4TB
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Clinical trial design Conducting clinical trials
2
COMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Keywords: IMI projects Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials
3
COMBACTE-MAGNET
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Keywords: IMI projects Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks
4
GNA NOW
Novel Gram-negative antibiotic now
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials
5
ND4BB
New Drugs for Bad Bugs. Umbrella programme comprising the IMI projects TRANSLOCATION, ENABLE, COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET, COMBACTE-CDI, iABC and DRIVE-AB
Keywords: IMI projects Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks Real-world data, evidence Drug discovery Economic model
6
RespiriNTM
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials Target identification
7
RespiriTB
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials
8